Production of Biotechnological APIs
Glatt Pharma+Biotech Engineering services for the production of YOUR biotechnological active pharmaceutical Ingredients
Glatt Pharma+Biotech Engineering services for the production of YOUR biotechnological active pharmaceutical Ingredients
In the evolving landscape of pharmaceuticals, Biotechnological Active Pharmaceutical Ingredients (APIs) represent a frontier of innovation, offering groundbreaking solutions to complex health challenges. Glatt Process & Plant Engineering is at the vanguard of this revolution, providing comprehensive engineering solutions that span from the initial concept to the final stages of production and compliance.
Our journey together begins with a deep dive into your biotechnological processes, where our seasoned experts apply their vast knowledge to refine and optimize each step. This includes the design of bespoke bioreactors that enhance cell culture efficiencies and the implementation of cutting-edge downstream processing techniques for the highest purity and yield. We understand that the production environment is as critical as the process itself. Therefore, our facility design not only adheres to the stringent standards of regulatory compliance but also integrates sustainable practices, ensuring a minimal environmental footprint and stand of the art technology.
As we navigate the complex pathway to commercialization, our team provides unwavering support in engineering, consulting and project management, ensuring your project progresses smoothly from blueprint to market. With Glatt, your biotechnological API production is poised not just for success but for leadership in the competitive pharmaceutical landscape.
Modular design approach for a production of biotechnological API: A layout with a deliberately decoupled building structure enables parallel flexibility in the different levels of use of new biotech and pharmaceutical factories: 1 = cleanroom, 2 = walkable cleanroom ceiling, 3 = air handling units and technical level
Modular multiproduct facilities for API synthesis not only make it possible to produce several different products for a lower investment, they can also be planned and delivered in a shorter timeframe because the engineering effort is much lower and field-proven solutions are used.
A modular design simplifies maintenance, which means that synthetic processes can be optimised and adapted to new requirements by selecting suitable modular connections. Predefined modules and proven layouts can be used to achieve “right-first-time” plant design.
Further information on this topic and related topics can also be found in the following publications:
December 2023: Glatt wins follow-up order for BioCampus MultiPilot in the port of Straubing-Sand
Published article: ‘The design and modularisation of API synthesis plants’ PDF, English
Published article: ‘How to move biopharmaceuticals productions smoothly and quickly into Asian markets’ PDF, Englisch
Published article: ‘High Containment Processes in the Solid Drugs Production’ PDF, Englisch